23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its therapeutics business and winding down its clinical trials; it expects these changes to save $35 million annually. On Tuesday, 23andMe reported $44 million in revenue during the second quarter, a decline from $50 million during the same period last year. The mass workforce reductions mark the latest disruption in a tumultuous year for 23andMe. In September, 23andMe’s entire board of directors — including Silicon Valley icons such as YouTube CEO Neal Mohan — resigned following Wojcicki’s attempt to take the company private in August. Read more on 23andMe's layoffs at the link in the bio 👆 Article by Maxwell Zeff Image Credits: ERIC BARADAT / Contributor / Getty Images #TechCrunch #technews #layoffs #biotech #healthtech #startup #founder